palmidrol has been researched along with 2019 Novel Coronavirus Disease in 12 studies
palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection
palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with long COVID olfactory dysfunction were allocated to different groups based on the presence ("previously treated") or absence ("naïve") of prior exposure to olfactory training." | 3.11 | Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study. ( Brenner, MJ; Camaioni, A; Carriere, G; De Luca, P; Di Stadio, A; Marra, P; Montemurro, N; Pucci, R; Ricciardi, L; Salzano, G, 2022) |
| "Long COVID is a recognized post-viral syndrome characterized by neurological, somatic and neuropsychiatric symptoms that might last for long time after SARS-CoV-2 infection." | 1.91 | What Is the Role of Palmitoylethanolamide Co-Ultramicronized with Luteolin on the Symptomatology Reported by Patients Suffering from Long COVID? A Retrospective Analysis Performed by a Group of General Practitioners in a Real-Life Setting. ( Bartolucci, F; Bellucci, AM; Ciaramaglia, PL; Cuzzocrea, S; Evangelista, M; Ferri, L; Lucangeli, M; Piccioni, L; Piga, A; Pirro, M; Russo, A; Russo, AM, 2023) |
| "We included only long COVID patients who were treated with PEA 600 mg two times daily for about 3 months." | 1.72 | The Use of Palmitoylethanolamide in the Treatment of Long COVID: A Real-Life Retrospective Cohort Study. ( Arcadi, FA; Calabrò, RS; De Luca, R; Raciti, G; Raciti, L, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 12 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| D'Amico, R | 1 |
| Monaco, F | 1 |
| Siracusa, R | 1 |
| Cordaro, M | 1 |
| Fusco, R | 1 |
| Peritore, AF | 1 |
| Gugliandolo, E | 1 |
| Crupi, R | 1 |
| Cuzzocrea, S | 2 |
| Di Paola, R | 1 |
| Impellizzeri, D | 1 |
| Genovese, T | 1 |
| Di Stadio, A | 4 |
| D'Ascanio, L | 2 |
| Vaira, LA | 1 |
| Cantone, E | 1 |
| De Luca, P | 3 |
| Cingolani, C | 2 |
| Motta, G | 1 |
| De Riu, G | 1 |
| Vitelli, F | 2 |
| Spriano, G | 1 |
| De Vincentiis, M | 1 |
| Camaioni, A | 3 |
| La Mantia, I | 2 |
| Ferreli, F | 2 |
| Brenner, MJ | 4 |
| Raciti, L | 1 |
| De Luca, R | 1 |
| Raciti, G | 1 |
| Arcadi, FA | 1 |
| Calabrò, RS | 1 |
| Marra, P | 1 |
| Salzano, G | 1 |
| Carriere, G | 1 |
| Ricciardi, L | 1 |
| Pucci, R | 1 |
| Montemurro, N | 1 |
| Fessler, SN | 1 |
| Liu, L | 1 |
| Chang, Y | 1 |
| Yip, T | 1 |
| Johnston, CS | 1 |
| Versace, V | 3 |
| Ortelli, P | 3 |
| Dezi, S | 3 |
| Ferrazzoli, D | 3 |
| Alibardi, A | 3 |
| Bonini, I | 3 |
| Engl, M | 3 |
| Maestri, R | 3 |
| Assogna, M | 3 |
| Ajello, V | 3 |
| Pucks-Faes, E | 3 |
| Saltuari, L | 3 |
| Sebastianelli, L | 3 |
| Kofler, M | 3 |
| Koch, G | 3 |
| Gallina, S | 1 |
| Cocuzza, S | 1 |
| Ingrassia, A | 1 |
| Oliva, S | 1 |
| Sireci, F | 1 |
| Mercante, G | 1 |
| Gaino, F | 1 |
| Pace, GM | 1 |
| Pirro, M | 1 |
| Ferri, L | 1 |
| Piccioni, L | 1 |
| Bellucci, AM | 1 |
| Bartolucci, F | 1 |
| Russo, A | 1 |
| Piga, A | 1 |
| Ciaramaglia, PL | 1 |
| Lucangeli, M | 1 |
| Russo, AM | 1 |
| Evangelista, M | 1 |
| Gigante, A | 1 |
| Aquili, A | 1 |
| Farinelli, L | 1 |
| Caraffa, A | 1 |
| Ronconi, G | 1 |
| Enrica Gallenga, C | 1 |
| Tetè, G | 1 |
| Kritas, SK | 1 |
| Conti, P | 1 |
| Roncati, L | 1 |
| Lusenti, B | 1 |
| Pellati, F | 1 |
| Corsi, L | 1 |
| Maranzano, M | 1 |
| Uberti, F | 1 |
| Ruga, S | 1 |
| Farghali, M | 1 |
| Galla, R | 1 |
| Molinari, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Palmitoylethanolamide on Proinflammatory Markers in Adults Recently Diagnosed With COVID-19[NCT04912921] | 115 participants (Actual) | Interventional | 2020-10-20 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for palmidrol and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Micronized / ultramicronized palmitoylethanolamide (PEA) as natural neuroprotector against COVID-19 inflammation.
Topics: Amides; Anti-Inflammatory Agents; Antiphospholipid Syndrome; COVID-19; COVID-19 Drug Treatment; Etha | 2021 |
6 trials available for palmidrol and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo- Controlled Clinical Trial.
Topics: Amides; COVID-19; Dietary Supplements; Ethanolamines; Humans; Luteolin; Olfaction Disorders; Palmiti | 2022 |
Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study.
Topics: Amides; COVID-19; COVID-19 Drug Treatment; Ethanolamines; Female; Humans; Longitudinal Studies; Lute | 2022 |
Palmitoylethanolamide Reduces Proinflammatory Markers in Unvaccinated Adults Recently Diagnosed with COVID-19: A Randomized Controlled Trial.
Topics: Adult; Amides; Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; COVID-19; Double-Blind Meth | 2022 |
Co-ultramicronized palmitoylethanolamide/luteolin normalizes GABA
Topics: Adult; COVID-19; Evoked Potentials, Motor; Fatigue; Female; gamma-Aminobutyric Acid; Humans; Luteoli | 2023 |
Co-ultramicronized palmitoylethanolamide/luteolin normalizes GABA
Topics: Adult; COVID-19; Evoked Potentials, Motor; Fatigue; Female; gamma-Aminobutyric Acid; Humans; Luteoli | 2023 |
Co-ultramicronized palmitoylethanolamide/luteolin normalizes GABA
Topics: Adult; COVID-19; Evoked Potentials, Motor; Fatigue; Female; gamma-Aminobutyric Acid; Humans; Luteoli | 2023 |
Co-ultramicronized palmitoylethanolamide/luteolin normalizes GABA
Topics: Adult; COVID-19; Evoked Potentials, Motor; Fatigue; Female; gamma-Aminobutyric Acid; Humans; Luteoli | 2023 |
Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial.
Topics: COVID-19; Humans; Luteolin; Olfaction Disorders; Olfactory Training; Smell | 2023 |
Randomized clinical trial "olfactory dysfunction after COVID-19: olfactory rehabilitation therapy vs. intervention treatment with Palmitoylethanolamide and Luteolin": preliminary results.
Topics: Adult; Amides; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; COVID-19; COVID-19 Drug Tr | 2021 |
5 other studies available for palmidrol and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Ultramicronized Palmitoylethanolamide in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation.
Topics: Amides; Animals; Blood Coagulation Disorders; COVID-19; Cytokines; Disease Models, Animal; Dissemina | 2021 |
The Use of Palmitoylethanolamide in the Treatment of Long COVID: A Real-Life Retrospective Cohort Study.
Topics: Adult; Amides; COVID-19; COVID-19 Drug Treatment; Ethanolamines; Female; Humans; Male; Middle Aged; | 2022 |
What Is the Role of Palmitoylethanolamide Co-Ultramicronized with Luteolin on the Symptomatology Reported by Patients Suffering from Long COVID? A Retrospective Analysis Performed by a Group of General Practitioners in a Real-Life Setting.
Topics: COVID-19; General Practitioners; Humans; Luteolin; Post-Acute COVID-19 Syndrome; Retrospective Studi | 2023 |
Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19.
Topics: Amides; Animals; Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cromol | 2020 |
A Combination of α-Lipoic Acid (ALA) and Palmitoylethanolamide (PEA) Blocks Endotoxin-Induced Oxidative Stress and Cytokine Storm: A Possible Intervention for COVID-19.
Topics: COVID-19; Cytokine Release Syndrome; Cytokines; Endotoxins; Humans; Lipopolysaccharides; Oxidative S | 2023 |